Fiona Maxwell

Slough, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'.

Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'.

Journal: ESMO open
Published: May 22, 2026

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.

Journal: Future oncology (London, England)
Published: May 04, 2026

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

Journal: ESMO open
Published: August 13, 2025

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.

Journal: ESMO open
Published: February 18, 2025

Corrigendum to "Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review" [Eur J Cancer 198 (2024) 113471].

Corrigendum to "Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review" [Eur J Cancer 198 (2024) 113471].

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 03, 2024

Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review.

Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review.

Journal: European journal of cancer (Oxford, England : 1990)
Published: September 11, 2023

Determining the Prevalence and Incidence of SARS-CoV-2 Infection in Prisons in England: Protocol for a Repeated Panel Survey and Enhanced Outbreak Study.

Determining the Prevalence and Incidence of SARS-CoV-2 Infection in Prisons in England: Protocol for a Repeated Panel Survey and Enhanced Outbreak Study.

Journal: JMIR research protocols
Published: May 27, 2021

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.

Journal: CPT: pharmacometrics & systems pharmacology
Published: January 15, 2021

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: December 04, 2020

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.

Journal: Breast cancer research and treatment
Published: July 15, 2020

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

Journal: Cancer treatment reviews
Published: October 20, 2015
Showing 1-11 of 11

Last Updated: 09/26/2026